Has Reetu Singh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,405 in general payments to Reetu Singh, MD across 415 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Reetu Singh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Reetu Singh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Reetu Singh, MD

Endocrinology, Diabetes & Metabolism · Lewes, DENPI 1275534737

Payments from drug & device makers

$9,405in general payments, 2019–2025

Across 415 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$1K
Lilly USA, LLC$1K
Novo Nordisk$976
Boehringer Ingelheim$758
Corcept Therapeutics$435
Abbott$334
plus $5K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	38	$1,070
Lilly USA, LLC	43	$1,042
Novo Nordisk	50	$976
Boehringer Ingelheim	31	$758
Corcept Therapeutics	16	$435
Abbott	16	$334
Bayer	14	$285
Insulet Corporation	11	$251
Amneal Pharmaceuticals LLC	13	$241
Harmony Biosciences LLC	8	$232
Sanofi-aventis U.S. LLC	13	$229
AstraZeneca(2 entities)	13	$221
Dexcom, Inc.	10	$216
Radius Health, Inc.	7	$179
Tandem Diabetes Care, Inc.	7	$179
Genentech USA, Inc.	6	$176
Actelion Pharmaceuticals US, Inc.	6	$162
Mallinckrodt Hospital Products Inc.	6	$161
Medtronic(2 entities)	4	$134
Xeris Pharmaceuticals, Inc.	6	$130
Novartis	6	$121
AbbVie	6	$120
ANI Pharmaceuticals, Inc.	5	$115
Verona Pharma, Inc.	6	$111
United Therapeutics Corporation	4	$106
Sunovion Pharmaceuticals Inc.	6	$98
Takeda Pharmaceuticals U.S.A., Inc.	3	$97
Esperion Therapeutics, Inc.	4	$84
Jazz Pharmaceuticals Inc.	4	$84
BETA Bionics, Inc.	3	$83
Grifols USA, LLC	3	$70
Amarin Pharma, Inc.	3	$60
Shire North American Group Inc	4	$59
Lifescan, Inc.	3	$54
Madrigal Pharmaceuticals	2	$53
Recordati_rare_diseases_inc.	2	$44
Axsome Therapeutics, Inc.	2	$43
Tactile Systems Technology Inc	2	$43
Avadel CNS Pharmaceuticals, LLC	2	$43
Chiesi USA, Inc.	2	$42
Sequel Med Tech, LLC	1	$37
Cequr Corporation	2	$34
Mallinckrodt Enterprises LLC	2	$33
Electromed, Inc.	2	$32
Philips North America LLC	2	$32
BD	1	$29
Johnson & Johnson	2	$28
Averitas Pharma Inc.	1	$27
Rhythm Pharmaceuticals, Inc.	1	$25
Ultragenyx Pharmaceutical Inc.	1	$24
Pfizer	1	$20
Regeneron Healthcare Solutions, Inc.	1	$19
Circassia Inc.	1	$18
Resmed Corp	1	$18
GSK	1	$16
Baxter Healthcare	1	$16
Mylan Specialty L.p.	1	$15
Eisai Inc.	1	$15
Merck	1	$13
Gilead	1	$12

How this compares

$9,405 in reported general payments places this provider in the 85th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.

See all endocrinology, diabetes & metabolism providers in Delaware →

Medicare billing

Part B allowed, 2024

$522,925

Medicare patients

770

Services billed

22,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lewes

Avinash RavipatiLewes$3K
Carlton BoxhillLewes$1K
Ripudaman HundalNewark$370K
Francisco PadillaSeaford$32K
Chitra ChoudharyDover$31K
Nira MadisiMilford$23K
Joanna KhatibMillsboro$7K
Ahmad ElayyanMillsboro$4K
Sheetal BulchandaniNewark$4K
Marc LaufgrabenNewark$2K

See the full list for Delaware →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →